Moderna, Inc. (MRNA)

49.24 -3.6 (-6.82%)

As of 2026-03-03 12:10:26 EST

Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Traded asNasdaq: MRNA
ISINUS60770K1079
CIK0001682852
LEI549300EI6OKH5K5Q2G38
EIN813467528
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOStéphane Bancel
Employees4,800
Fiscal Year End1231
Address325 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone6177146500
Websitehttp://modernatx.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
MRNAModerna, Inc.2026-03-03 12:10:2649.24-3.6-6.82
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
MRNA0001682852Moderna, Inc.US60770K1079549300EI6OKH5K5Q2G38813467528Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE325 BINNEY STREETCAMBRIDGEMA02142UNITED STATESUS6177146500325 BINNEY STREET, CAMBRIDGE, MA, 02142325 BINNEY STREET, CAMBRIDGE, MA, 02142Moderna Therapeutics, Inc.Biotechnology2010Stéphane Bancel4,800http://modernatx.com9,900,000,000394,000,000394,939,424Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".2026-02-26 15:48:46
This is a preview of the latest data. Subscribe to access the full data.
MRNA Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
MRNA Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20259,900,000,000-32,200,000,000-76.4846394,939,4249,123,5472.3647
202442,100,000,0001,900,000,0004.7264385,815,8773,742,6690.9796
202340,200,000,000-8,600,000,000-17.623382,073,208-4,266,386-1.1043
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Shannon Thyme KlingerChief Legal Officer, Corporate Secretary2024829,468011,507,317763,77615,52517,368,701
Stephen HogePresident20241,083,92304,422,6981,447,99215,5259,181,478
Stéphane BancelChief Executive Officer20241,625,88507,654,7301,965,600975,21319,876,180
Arpa GarayChief Commercial Officer2023842,30801,460,282619,65063,4134,445,948
James MockChief Financial Officer2023792,30801,460,282583,20021,1004,317,185
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20254,700
20245,800
20235,600
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue1,944,000,0003,236,000,0006,848,000,000
Cost Of Revenue868,000,0001,464,000,0004,693,000,000
Gross Profit———
Research And Development Expenses3,132,000,0004,543,000,0004,845,000,000
General And Administrative Expenses1,018,000,0001,174,000,0001,549,000,000
Operating Expenses5,018,000,0007,181,000,00011,087,000,000
Operating Income-3,074,000,000-3,945,000,000-4,239,000,000
Net Income-2,822,000,000-3,561,000,000-4,714,000,000
Earnings Per Share Basic-7.26-9.28-12.33
Earnings Per Share Diluted-7.26-9.28-12.33
Weighted Average Shares Outstanding Basic389,000,000384,000,000382,000,000
Weighted Average Shares Outstanding Diluted389,000,000384,000,000382,000,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents2,595,000,0001,927,000,0002,907,000,000
Marketable Securities Current3,204,000,0005,098,000,0005,697,000,000
Accounts Receivable184,000,000358,000,000892,000,000
Inventories153,000,000117,000,000202,000,000
Non Trade Receivables8,000,00072,000,00019,000,000
Other Assets Current45,000,00058,000,00088,000,000
Total Assets Current6,544,000,0008,099,000,00010,325,000,000
Marketable Securities Non Current2,336,000,0002,494,000,0004,677,000,000
Property Plant And Equipment———
Other Assets Non Current605,000,000594,000,000685,000,000
Total Assets Non Current5,794,000,0006,043,000,0008,101,000,000
Total Assets12,338,000,00014,142,000,00018,426,000,000
Accounts Payable317,000,000405,000,000520,000,000
Deferred Revenue99,000,000153,000,000568,000,000
Short Term Debt———
Other Liabilities Current185,000,000221,000,00066,000,000
Total Liabilities Current1,987,000,0002,206,000,0003,015,000,000
Long Term Debt590,000,000——
Other Liabilities Non Current285,000,000267,000,000256,000,000
Total Liabilities Non Current1,701,000,0001,035,000,0001,557,000,000
Total Liabilities3,688,000,0003,241,000,0004,572,000,000
Common Stock000
Retained Earnings7,223,000,00010,045,000,00013,606,000,000
Accumulated Other Comprehensive Income45,000,000-10,000,000-123,000,000
Total Shareholders Equity8,650,000,00010,901,000,00013,854,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization211,000,000185,000,000617,000,000
Share Based Compensation Expense483,000,000429,000,000305,000,000
Other Non Cash Income Expense-77,000,000-60,000,000-7,000,000
Change In Accounts Receivable-156,000,000-534,000,000-493,000,000
Change In Inventories34,000,000-83,000,000-747,000,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-92,000,000-69,000,00013,000,000
Change In Other Liabilities-6,000,00078,000,00073,000,000
Cash From Operating Activities-1,873,000,000-3,004,000,000-3,118,000,000
Purchases Of Marketable Securities5,768,000,0006,529,000,0003,760,000,000
Sales Of Marketable Securities2,353,000,0003,967,000,0003,206,000,000
Acquisition Of Property Plant And Equipment192,000,0001,051,000,000707,000,000
Acquisition Of Business0085,000,000
Other Investing Activities———
Cash From Investing Activities1,946,000,0001,949,000,0004,206,000,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock35,000,00066,000,00046,000,000
Repurchase Of Common Stock2,000,00001,153,000,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities593,000,00056,000,000-1,377,000,000
Change In Cash668,000,000-999,000,000-289,000,000
Cash At End Of Period2,595,000,0001,927,000,0002,907,000,000
Income Taxes Paid26,000,000197,000,000-357,000,000
Interest Paid10,000,00024,000,00039,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-7.26-9.28-12.33
Price To Earnings Ratio-4.062-4.4806-8.0657
Earnings Growth Rate-21.7672-24.7364-157.9962
Price Earnings To Growth Ratio0.18660.18110.051
Book Value Per Share22.236528.38836.267
Price To Book Ratio1.32621.46472.7422
Ebitda-2,585,000,000-3,179,000,000-4,454,000,000
Enterprise Value9,466,610,000——
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.0682——
Capital Expenditures———
Free Cash Flow———
Return On Equity-0.3262-0.3267-0.3403
One Year Beta1.26451.45971.0272
Three Year Beta1.23221.41921.2162
Five Year Beta1.24370.62810.6204
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Hoge StephenPresident2026-02-23111,679A1,569,106
Hoge StephenPresident2026-02-2348,330A1,617,436
Hoge StephenPresident2026-02-23160,009D1,457,427
Hoge StephenPresident2026-02-23111,679D111,678
Hoge StephenPresident2026-02-2348,330D48,330
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Rob Bresnahan2025-05-08PA08Sale2025-04-08—$1,001 - $15,000
Rob Bresnahan2025-03-27PA08Purchase2025-02-25—$1,001 - $15,000
Julie Johnson2025-02-12TX32Sale2025-01-15Joint$1,001 - $15,000
Josh Gottheimer2024-03-07NJ05Sale2024-02-01Joint$1,001 - $15,000
Josh Gottheimer2023-10-15NJ05Sale2023-09-15Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
TOBAM2025-12-311,362,00046,18929.4875
Banque Transatlantique SA2025-12-31618,99220,41830.316
Bell Investment Advisors, Inc2025-12-312,2127529.4933
CHELSEA COUNSEL CO2025-12-312,94910029.49
Pacer Advisors, Inc.2025-12-31803,48527,24629.49
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
PIMCO Equity Series2025-12-31PIMCO RAFI ESG U.S. ETFRAFE12,072356,003.280.2977
RYDEX SERIES FUNDS2025-12-31Class HRYNHX1,23736,479.130.014
RYDEX SERIES FUNDS2025-12-31Class CRYNCX1,23736,479.130.014
RYDEX SERIES FUNDS2025-12-31Class ARYANX1,23736,479.130.014
RYDEX SERIES FUNDS2025-12-31Investor ClassRYNVX1,23736,479.130.014
This is a preview of the latest data. Subscribe to access the full data.